SecBot SecBot
SECBOTREPLAY Home › Report › NMRA

NMRA · Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3…

Neumora Therapeutics, Inc. · 8-K filed Jun 15, 2026 at 08:15 ET

At the news

BEARISHIMPACT 7/10

8-K filed Jun 15, 2026 at 08:15 ET

Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3 studies of navacaprant for major depressive disorder failed to achieve statistical significance on the primary endpoint, leading to discontinuation of its lead pipeline asset. The company is implementing a 35% workforce reduction to generate ~$10M in annualized savings, incurring ~$2M in restructuring costs, and amended its loan agreement to extend the interest-only period and adjust liquidity covenants. Cash runway is extended into Q3 2027, but the loss of the most advanced program is a severe setback for this clinical-stage biotech.

  • Phase 3 KOASTAL-2 (n=430) and KOASTAL-3 (n=422) both failed primary endpoint (MADRS change from baseline at week 6); p-values 0.813 and 0.480 respectively
  • Navacaprant development discontinued entirely
  • Workforce reduction of approximately 35% implemented on June 12, 2026
  • Expected annualized cost savings of ~$10 million from the reduction in force

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access